申请人:The Genetics Company, Inc.
公开号:EP1932830A1
公开(公告)日:2008-06-18
The present invention relates to the use of a sulfonamide compound of formula I:
wherein
R1 is selected from the group consisting of H, CN, halogen, trifluoromethyl, methyl, ethyl, hydroxyl, methoxyl, ethoxyl, morpholinyl, R2 is selected from H, phenyl, substituted phenyl, CN, -SO2R, wherein R is phenyl or morpholinyl, -NC(O)Me, -NC(O)Et, - CH2C(O)OMe, CH2C(O)OEt, R3 is selected from the group consisting of H, NO2 NH2, halogen, -COOMe, -COOEt, RC(O)N-, morpholino, R4 is selected from the group consisting of H, a branched or unbranched methyl, ethyl, propyl, butyl, pentyl, methoxyl, ethoxyl, propoxyl, butoxyl, a substituted or unsubstituted phenyl, alkynyl, Me2SO2-, COOR, wherein R is a branched or unbranched methyl, ethyl, propyl, butyl, pentyl, - MeOC(O)-, a substituted or unsubstituted five or six-membered aromatic or non-aromatic heterocyclic system with one , two or three heteroatoms, a heteroaryl system, a condensed benzoheterocyclic system, X is a linker comprising 2 or 3 atoms, selected from the group consisting of -NH-NH-, -NH-NH-CH2-, ethynyl, -NH-C(O)-CH2-, -NH-NH-SO2- -C(O)-NH-CH2-, -NH-N=CH-, -NH-N=C(Me)-, a -NH-N=CH- motif being part of a heterocyclic system, preferably a substituted or unsubstituted pyrazole or pyridazine system, and pharmaceutically active salts thereof. Further, the invention relates to the use of these compounds as a medicament, especially for the treatment of cancer.
本发明涉及使用式I的磺胺化合物:
其中
R1选自H、CN、卤素、三氟甲基、甲基、乙基、羟基、甲氧基、乙氧基、吗啉基中的一种;
R2选自H、苯基、取代苯基、CN、-SO2R中的一种,其中R为苯基或吗啉基,-NC(O)Me、-NC(O)Et、-CH2C(O)OMe、CH2C(O)OEt中的一种;
R3选自H、NO2、NH2、卤素、-COOMe、-COOEt、RC(O)N-、吗啉基中的一种;
R4选自H、支链或非支链的甲基、乙基、丙基、丁基、戊基、甲氧基、乙氧基、丙氧基、丁氧基、取代或未取代的苯基、炔基、Me2SO2-、COOR中的一种,其中R为支链或非支链的甲基、乙基、丙基、丁基、戊基、-MeOC(O)-、取代或未取代的五元或六元芳香或非芳香杂环系统,带有一个、两个或三个杂原子的杂环芳基系统,一个紧凑的苯并杂环系统,X是包含2或3个原子的连接物,选自-NH-NH-、-NH-NH-CH2-、乙炔基、-NH-C(O)-CH2-、-NH-NH-SO2-、-C(O)-NH-CH2-、-NH-N=CH-、-NH-N=C(Me)-、-NH-N=CH-基团是杂环系统的一部分,优选为取代或未取代的吡唑或吡啶嘧啶系统,以及其药用活性盐。此外,本发明涉及将这些化合物用作药物,特别用于癌症治疗。